Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Cognitive Function

Not Applicable

Completed

• Conditions: Cognitive Function
• Interventions: Dietary Supplement: Hydrolysed Red Ginseng Extract; Dietary Supplement: Placebo

• Registration Number: NCT04184388
• Lead Sponsor: Chonbuk National University Hospital

Brief Summary

This study was the evaluate the efficacy and safety of hydrolysed red ginseng extract on the improvement of Cognitive Function

Detailed Description

This study was 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate. 100 subjects participated in hydrolysed red ginseng extract or placebo group. To evaluate the changes in the evaluation items when hydrolysed red ginseng extract was taken 12 weeks compared with placebo.

Study Timeline

• Study Start: 2019-11-01
• Study First Submitted: 2019-11-29
• Study First Submitted QC: 2019-11-29
• Study First Posted: 2019-12-03
• Primary Completion: 2020-09-28
• Study Completion: 2020-11-30
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-25
• Last Update Posted: 2021-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Persons who are at least 60 years of age at screening
• Persons who have Korean Mini-Mental Status Examination(K-MMSE) result in 25-28 points
• Persons who agree to voluntary participation and to comply with the Notice after fully hearing and understanding the details of this human trial

Exclusion Criteria

• Patients with a past history of treatment with Axis I disorder in SCID(Structured Clinical Interview for DSM-IV) which is a structured clinical interview in the Diagnostic and Statistical Manual of Mental Disorders at Screening or who have been treated within the last 3 years

• Patients with BMI(Body Mass Index)<18.5 kg/m^ or 35 kg/m^≤BMI(Body Mass Index)

• Patients with alcohol abuse or dependence within the last 3 months

• Patients who have clinically significant following severe illness (i.e., Cardiovascular, endocrine system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, neuropsychiatric, musculoskeletal, inflammatory, blood and tumors, gastrointestinal diseases, etc.)

• Patients with a history of clinically significant hypersensitivity to ginseng or red ginseng

• Patients taking medicines, health functional foods or herbal medicines related to the improvement of cognitive function and memory within 1 month before screening

• Patients who ingested ginseng and red ginseng extract's health functional food within 1 month before screening

• Patients who whole blood donation within 1 months before the first ingestion or Component blood donation within 2 weeks

• Patients who participate in another human trial within 3 months

• Those who show the following results in the Laboratory test

  • AST, ALT > 3 times upper limit of the normal range
  • Other significant laboratory test opinion

• Patients who are deemed unsuitable for participating in the human trial due to other reasons

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Hydrolysed Red Ginseng Extract	Hydrolysed Red Ginseng Extract	Hydrolysed Red Ginseng extract for 1g/day
Placebo	Placebo	Hydrolysed Red Ginseng extract for 0g/day

Primary Outcome Measures

Name	Time	Method
Visual working memory test	12 weeks	Visual working memory test was measured in baseline and 12 week.
Visual learning test	12 weeks	Visual learning test was measured in baseline and 12 week.
MoCA-K; Korean Version of the Montreal Cognitive Assessment	12 weeks	Korean Version of the Montreal Cognitive Assessment(MoCA-K) was measured in baseline and 12 week. The cognitive function evaluation using the Montreal Cognitive Assessment(MoCA-K) is a total of 8 items, and evaluates cognitive functions such as time / execution power, vocabulary, memory, attention, sentence, abstraction, delayed recall, and orientation.; Time / execution power's total score is 5 points, vocabulary's total score is 3 points, attention's total score is 3 points, sentence's total score is 3 points, abstraction's total score is 2 points, delayed recall's total score is 5 points, orientation's total score is 6 points. It takes about 10 minutes to complete, and the total score is 30 points and total score make sum score. A score of 23 points or more is regarded as normal. If you have less than 6 years of education, add 1 point.

Secondary Outcome Measures

Name	Time	Method
Verbal learning test	12 weeks	Verbal learning test was measured in baseline and 12 week.
Auditory continuous performance test	12 weeks	Auditory continuous performance test was measured in baseline and 12 week.
BDI; Beck Depression Inventory	12 weeks	Beck Depression Inventory(BDI) was measured in baseline and 12 week. It consists of 21 items including cognitive, emotional, synchronous, and physical symptoms of depression. The total score ranges from 0\~63 points for each question. Beck Depression Inventory(BDI) score is 0 \~ 9 points non-depression, 10 \~ 15 is mild depression, 16 \~ 23 is moderate depression, and 24 \~ 63 is severe depression.
PSS; Perceived stress scale	12 weeks	Perceived stress scale(PSS) was measured in baseline and 12 week. It consists of 10 questions. Each question is evaluated from 0 (none) to 4 (very often), and 4 items (4, 5, 7, 8) are scored back and added to the remaining questions. The duration of the last month should be presented before implementation (if the duration is longer, the predictability is lowered).
BDNF; Brain-derived neurotrophic factor	12 weeks	Brain-derived neurotrophic factor(BDNF)(pg/mL) was measured in baseline and 12 week.
TAS(Total antioxidant status)	12 weeks	Total antioxidant status(TAS) was measured in baseline and 12 week.

Trial Locations

Locations (1)

Department of Psychiatry, Chonbuk National University Hospital; 🇰🇷 Jeonju, Jeollabuk-do, Korea, Republic of